Eidos Therapeutics Inc (NASDAQ:EIDX) Receives Consensus Rating of “Buy” from Analysts

Share on StockTwits

Shares of Eidos Therapeutics Inc (NASDAQ:EIDX) have earned an average recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $30.20.

EIDX has been the topic of several research analyst reports. BTIG Research set a $14.00 price target on ARBOR RLTY TR I/SH and gave the company a “buy” rating in a research note on Wednesday, April 17th. BMO Capital Markets downgraded Capital Power from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 8th. Finally, Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th.

EIDX stock traded down $1.61 on Wednesday, hitting $39.14. 236,303 shares of the company’s stock were exchanged, compared to its average volume of 144,430. Eidos Therapeutics has a 12-month low of $8.89 and a 12-month high of $41.35. The stock’s 50 day simple moving average is $32.70. The company has a current ratio of 19.04, a quick ratio of 19.04 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.50 billion and a PE ratio of -21.04.

Eidos Therapeutics (NASDAQ:EIDX) last announced its earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). As a group, sell-side analysts forecast that Eidos Therapeutics will post -1.73 earnings per share for the current year.

In other news, insider Uma Sinha sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $27.28, for a total value of $136,400.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Christine Siu sold 17,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $29.97, for a total value of $509,490.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,000 shares of company stock worth $2,305,940.

Institutional investors and hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co NY purchased a new stake in Eidos Therapeutics in the 1st quarter valued at approximately $143,000. MetLife Investment Advisors LLC purchased a new stake in shares of Eidos Therapeutics during the 1st quarter worth approximately $198,000. Fiduciary Trust Co. purchased a new stake in shares of Eidos Therapeutics during the 1st quarter worth approximately $211,000. American International Group Inc. boosted its stake in shares of Eidos Therapeutics by 2.3% during the 1st quarter. American International Group Inc. now owns 245,362 shares of the company’s stock worth $5,754,000 after acquiring an additional 5,586 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of Eidos Therapeutics by 193.1% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 425,000 shares of the company’s stock worth $9,967,000 after acquiring an additional 280,000 shares in the last quarter. Hedge funds and other institutional investors own 34.01% of the company’s stock.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Featured Article: What is the Gross Domestic Product (GDP)?

Analyst Recommendations for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Weekly Investment Analysts’ Ratings Updates for Howard Bancorp
Weekly Investment Analysts’ Ratings Updates for Howard Bancorp
Ecoreal Estate  Hits 1-Day Trading Volume of $24,671.00
Ecoreal Estate Hits 1-Day Trading Volume of $24,671.00
Pinkerton Retirement Specialists LLC Takes $1.32 Million Position in iShares iBoxx $ Investment Grade Corporate Bond ETF
Pinkerton Retirement Specialists LLC Takes $1.32 Million Position in iShares iBoxx $ Investment Grade Corporate Bond ETF
Paragon Capital Management LLC Has $10.04 Million Holdings in TJX Companies Inc
Paragon Capital Management LLC Has $10.04 Million Holdings in TJX Companies Inc
Hanesbrands Inc.  Shares Bought by Pinkerton Retirement Specialists LLC
Hanesbrands Inc. Shares Bought by Pinkerton Retirement Specialists LLC
Paragon Capital Management LLC Raises Stock Position in ConocoPhillips
Paragon Capital Management LLC Raises Stock Position in ConocoPhillips


 
© 2006-2019 Zolmax.